奧士康(002913.SZ):公司海外業務正快速拓展
格隆匯4月27日丨有投資者在投資者互動平台向奧士康(002913.SZ)提問,“據説公司23年一季度海外訂單供不應求,這與公司走產品高端化轉型有關?公司在泰國的項目進展如何?”
奧士康回複稱,公司海外業務正快速拓展,一季度具體經營情況請關注屆時披露的2023年第一季度報吿。公司在持續推進研發創新,尤其是以新平台服務器及AI服務器為代表的高端產品的開發創新,以獲取高附加值訂單。 泰國項目目前正在積極籌備中,相關工作在持續推進,項目進度情況敬請關注後續披露的定期報吿及臨時公吿。泰國項目的建成將進一步開拓海外市場,打造海外供貨能力,優化公司產能佈局,實現內外雙循環,公司對未來3年的高速發展充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.